Wall Street analysts forecast that Intersect ENT Inc (NASDAQ:XENT) will announce earnings of ($0.35) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Intersect ENT’s earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.30). Intersect ENT reported earnings of ($0.16) per share in the same quarter last year, which would suggest a negative year over year growth rate of 118.8%. The business is expected to issue its next earnings results before the market opens on Monday, February 24th.

According to Zacks, analysts expect that Intersect ENT will report full-year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.50) to ($1.42). For the next financial year, analysts anticipate that the firm will post earnings of ($1.46) per share, with EPS estimates ranging from ($1.55) to ($1.39). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Intersect ENT.

XENT has been the topic of several recent analyst reports. BidaskClub upgraded Intersect ENT from a “hold” rating to a “buy” rating in a report on Thursday, January 16th. Piper Jaffray Companies set a $21.00 price objective on Intersect ENT and gave the stock a “hold” rating in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. boosted their price objective on Intersect ENT from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Intersect ENT currently has a consensus rating of “Hold” and an average target price of $27.25.

Large investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC purchased a new position in Intersect ENT during the 3rd quarter valued at about $36,000. Great West Life Assurance Co. Can purchased a new position in Intersect ENT during the 4th quarter valued at about $52,000. Meeder Asset Management Inc. grew its stake in Intersect ENT by 311.8% during the 4th quarter. Meeder Asset Management Inc. now owns 3,694 shares of the medical equipment provider’s stock valued at $91,000 after acquiring an additional 2,797 shares in the last quarter. Bank of Montreal Can grew its stake in Intersect ENT by 42.5% during the 4th quarter. Bank of Montreal Can now owns 3,838 shares of the medical equipment provider’s stock valued at $96,000 after acquiring an additional 1,144 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in Intersect ENT by 36.9% during the 4th quarter. Victory Capital Management Inc. now owns 6,778 shares of the medical equipment provider’s stock valued at $169,000 after acquiring an additional 1,827 shares in the last quarter. 96.87% of the stock is currently owned by institutional investors.

NASDAQ XENT traded up $0.22 on Friday, hitting $28.98. 670,730 shares of the company were exchanged, compared to its average volume of 702,382. The company’s 50 day moving average price is $25.24 and its 200-day moving average price is $20.40. The firm has a market capitalization of $852.48 million, a P/E ratio of -22.64 and a beta of 0.91. Intersect ENT has a twelve month low of $14.61 and a twelve month high of $35.87.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Recommended Story: Technical Indicators – What is a Golden Cross?

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.